{"id":77054,"date":"2026-08-28T20:48:47","date_gmt":"2026-08-28T12:48:47","guid":{"rendered":"https:\/\/flcube.com\/?p=77054"},"modified":"2026-08-28T20:48:48","modified_gmt":"2026-08-28T12:48:48","slug":"abbvie-submits-ema-application-for-skyrizi-subcutaneous-induction-in-crohns-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77054","title":{"rendered":"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn&#8217;s Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AbbVie<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) announced that it has submitted an application to the <strong>European Medicines Agency (EMA)<\/strong> for the <strong>SKYRIZI (risankizumab)<\/strong> subcutaneous (SC) induction regimen for the treatment of adult patients with moderately to severely active <strong>Crohn&#8217;s disease (CD)<\/strong>. If approved, the filing would give European patients the option to receive their induction doses entirely via SC injection \u2014 removing the need for intravenous infusion and further cementing <strong>SKYRIZI&#8217;s<\/strong> position as a leading IL-23 inhibitor in inflammatory bowel disease.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>European Medicines Agency (EMA)<\/strong><\/td><\/tr><tr><td>Submission Type<\/td><td>Application for new induction regimen<\/td><\/tr><tr><td>Product<\/td><td><strong>SKYRIZI (risankizumab)<\/strong> subcutaneous (SC) induction<\/td><\/tr><tr><td>Indication<\/td><td>Adults with moderately to severely active <strong>Crohn&#8217;s disease (CD)<\/strong><\/td><\/tr><tr><td>Date<\/td><td>27 Aug 2026<\/td><\/tr><tr><td>Current Status<\/td><td>Application submitted; pending EMA review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Risankizumab, marketed as <strong>SKYRIZI<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> Interleukin (IL)-23 \u2014 selectively blocked by binding to its p19 subunit<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> IL-23 is a cytokine involved in inflammatory processes and is thought to be linked to a number of chronic immune-mediated diseases<\/li>\n\n\n\n<li><strong>Current EU Position:<\/strong> In 2022, <strong>SKYRIZI<\/strong> became the first specific <strong>IL-23 inhibitor<\/strong> approved in the European Union for <strong>Crohn&#8217;s disease<\/strong>, indicated for adult patients with moderately to severely active CD who have had inadequate response, lost response, or were intolerant to conventional or biologic therapy<\/li>\n\n\n\n<li><strong>Approved Indications:<\/strong> Plaque psoriasis, psoriatic arthritis, Crohn&#8217;s disease, and ulcerative colitis \u2014 approved by both the <strong>U.S. Food and Drug Administration<\/strong> and the <strong>European Medicines Agency<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-patient-treatment-pathway-current-vs-proposed\" class=\"wp-block-heading\">Patient Treatment Pathway \u2013 Current vs. Proposed<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Current Regimen<\/th><th>If SC Induction Approved<\/th><\/tr><\/thead><tbody><tr><td>Induction<\/td><td>IV infusion (or SC option where approved)<\/td><td>Choice of SC injection or IV infusion<\/td><\/tr><tr><td>Maintenance<\/td><td>Subcutaneous doses every eight weeks<\/td><td>Subcutaneous doses every eight weeks (unchanged)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">If approved, patients with moderately to severely active <strong>CD<\/strong> would have the option to receive their <strong>SKYRIZI<\/strong> induction doses via SC injection or through IV infusion, and then continue subcutaneous maintenance doses every eight weeks. The all-subcutaneous pathway addresses a persistent patient preference for needle-based convenience over infusion-center visits in chronic IBD care.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Franchise Defense:<\/strong> The SC induction filing protects <strong>AbbVie&#8217;s<\/strong> established <strong>SKYRIZI<\/strong> franchise in <strong>Crohn&#8217;s disease<\/strong> against rivals advancing their own needle-free or subcutaneous induction strategies<\/li>\n\n\n\n<li><strong>Patient Preference Economics:<\/strong> Offering a choice between SC injection and IV infusion at induction broadens addressable uptake among patients and clinicians seeking to minimize infusion-center dependency<\/li>\n\n\n\n<li><strong>IL-23 Class Leadership:<\/strong> As the first specific IL-23 inhibitor approved for CD in the EU, <strong>SKYRIZI<\/strong> holds the incumbency advantage; streamlined dosing reinforces that first-mover position<\/li>\n\n\n\n<li><strong>Cross-Indication Synergy:<\/strong> With approvals spanning plaque psoriasis, psoriatic arthritis, CD, and ulcerative colitis from both the <strong>FDA<\/strong> and <strong>EMA<\/strong>, <strong>AbbVie<\/strong> leverages a single molecule across multiple immune-mediated markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding regulatory review, approval timing, and commercial potential. Regulatory submissions may not result in approval. Actual results may differ materially. Not investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77055,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[234,65,38,853],"class_list":["post-77054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbvie","tag-auto-immune","tag-market-approval-filings","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn&#039;s Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency (EMA) for the SKYRIZI (risankizumab) subcutaneous (SC) induction regimen for the treatment of adult patients with moderately to severely active Crohn&#039;s disease (CD). If approved, the filing would give European patients the option to receive their induction doses entirely via SC injection \u2014 removing the need for intravenous infusion and further cementing SKYRIZI&#039;s position as a leading IL-23 inhibitor in inflammatory bowel disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77054\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn&#039;s Disease\" \/>\n<meta property=\"og:description\" content=\"AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency (EMA) for the SKYRIZI (risankizumab) subcutaneous (SC) induction regimen for the treatment of adult patients with moderately to severely active Crohn&#039;s disease (CD). If approved, the filing would give European patients the option to receive their induction doses entirely via SC injection \u2014 removing the need for intravenous infusion and further cementing SKYRIZI&#039;s position as a leading IL-23 inhibitor in inflammatory bowel disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77054\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T12:48:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T12:48:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn&#8217;s Disease\",\"datePublished\":\"2026-08-28T12:48:47+00:00\",\"dateModified\":\"2026-08-28T12:48:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054\"},\"wordCount\":488,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2805.webp\",\"keywords\":[\"AbbVie\",\"Auto-immune\",\"Market approval filings\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77054#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77054\",\"name\":\"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2805.webp\",\"datePublished\":\"2026-08-28T12:48:47+00:00\",\"dateModified\":\"2026-08-28T12:48:48+00:00\",\"description\":\"AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency (EMA) for the SKYRIZI (risankizumab) subcutaneous (SC) induction regimen for the treatment of adult patients with moderately to severely active Crohn's disease (CD). If approved, the filing would give European patients the option to receive their induction doses entirely via SC injection \u2014 removing the need for intravenous infusion and further cementing SKYRIZI's position as a leading IL-23 inhibitor in inflammatory bowel disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77054\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2805.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn's Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77054#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn&#8217;s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency (EMA) for the SKYRIZI (risankizumab) subcutaneous (SC) induction regimen for the treatment of adult patients with moderately to severely active Crohn's disease (CD). If approved, the filing would give European patients the option to receive their induction doses entirely via SC injection \u2014 removing the need for intravenous infusion and further cementing SKYRIZI's position as a leading IL-23 inhibitor in inflammatory bowel disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77054","og_locale":"en_US","og_type":"article","og_title":"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn's Disease","og_description":"AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency (EMA) for the SKYRIZI (risankizumab) subcutaneous (SC) induction regimen for the treatment of adult patients with moderately to severely active Crohn's disease (CD). If approved, the filing would give European patients the option to receive their induction doses entirely via SC injection \u2014 removing the need for intravenous infusion and further cementing SKYRIZI's position as a leading IL-23 inhibitor in inflammatory bowel disease.","og_url":"https:\/\/flcube.com\/?p=77054","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-28T12:48:47+00:00","article_modified_time":"2026-08-28T12:48:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77054#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77054"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn&#8217;s Disease","datePublished":"2026-08-28T12:48:47+00:00","dateModified":"2026-08-28T12:48:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77054"},"wordCount":488,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77054#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2805.webp","keywords":["AbbVie","Auto-immune","Market approval filings","NYSE: ABBV"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77054#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77054","url":"https:\/\/flcube.com\/?p=77054","name":"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77054#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77054#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2805.webp","datePublished":"2026-08-28T12:48:47+00:00","dateModified":"2026-08-28T12:48:48+00:00","description":"AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency (EMA) for the SKYRIZI (risankizumab) subcutaneous (SC) induction regimen for the treatment of adult patients with moderately to severely active Crohn's disease (CD). If approved, the filing would give European patients the option to receive their induction doses entirely via SC injection \u2014 removing the need for intravenous infusion and further cementing SKYRIZI's position as a leading IL-23 inhibitor in inflammatory bowel disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77054#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77054"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77054#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2805.webp","width":1080,"height":608,"caption":"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn's Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77054#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn&#8217;s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2805.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77054"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77054\/revisions"}],"predecessor-version":[{"id":77056,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77054\/revisions\/77056"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77055"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}